Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 7/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.35 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16575842 | 1.00 | POLG (0.41) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL16575704 | 0.91 | POLG (0.42) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL17972031 | 0.91 | POLG (0.42) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL16575679 | 0.88 | POLG (0.44) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL17971998 | 0.88 | POLG (0.44) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL16575699 | 0.88 | POLG (0.44) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL21418452 | 0.88 | POLG (0.44) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL17972024 | 0.88 | POLG (0.44) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL21418707 | 0.87 | POLG (0.42) | POLGP2RY1P2RY2P2RY11P2RY4 | |
| SCHEMBL17972003 | 0.87 | POLG (0.42) | POLGP2RY1P2RY2P2RY11P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | POLG 448/4885P2RY1 198/4885P2RY2 452/4885 |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | POLG 601/4885P2RY1 163/4885P2RY2 316/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | POLG 788/4885P2RY1 30/4885P2RY2 89/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | POLG 448/4885P2RY1 198/4885P2RY2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.